Tamoxifen in the treatment of infertility associated with luteal phase deficiency

Fertility and sterility, 37(6), 755-761

DOI 10.1016/s0015-0282(16)46334-x PMID 6806128 Source

Abstract

A group of 17 patients with suspected luteal phase deficiency was treated with tamoxifen. Tamoxifen therapy was found to lengthen the luteal phase in all patients and resulted in pregnancy in 6 of 17 patients. The integrated luteal phase progesterone (P) concentration in the nontreatment cycle of seven patients was significantly lower (P less than 0.01) than that of five normal women. Therapy with tamoxifen increased the P concentration to 186.0 +/- 24.4 ng/ml/cycle (mean +/- standard error of the mean), i.e., twice that of the control cycle. The mean estradiol (E2) concentration at the midcycle peak was about twice that observed during the nontreatment cycle. The glycogen content of the endometrial tissue at the midluteal phase in the tamoxifen cycle was significantly higher (P less than 0.025) than that of endometrial tissue in the nontreatment cycle, indicating improvement of the endometrial function.

Topics

tamoxifen luteal phase deficiency treatment, luteal phase defect hormonal therapy, tamoxifen infertility progesterone support, luteal insufficiency pharmacological treatment, corpus luteum dysfunction medication, tamoxifen ovulation induction outcomes, endometrial function improvement fertility, short luteal phase treatment options, progesterone deficiency tamoxifen therapy

Cite this article

Fukushima, T., Tajima, C., Fukuma, K., & Maeyama, M. (1982). Tamoxifen in the treatment of infertility associated with luteal phase deficiency. *Fertility and sterility*, *37*(6), 755-761. https://doi.org/10.1016/s0015-0282(16)46334-x

Related articles